Phase II Study of TSR-022 in Combination with TSR-042 for the Treatment of Advanced Hepatocellular Carcinoma
The purpose of this study is to determine if giving TSR-022 and TSR-042 will shrink the tumor in participants with hepatocellular carcinoma (liver cancer).
-Histologically or cytologically confirmed hepatocellular cancer
-No prior systemic therapy
-Age ≥ 18 years
-Enrolled in another clinical trial
-Major surgery within 3 weeks of starting study drug
18 - 120
Healthy Volunteers Needed
Duration of Participation
You are able to participate, you will receive study drugs for up to 2 years. After stopping study drugs, you will be followed every 3 months until you withdraw from the study or the study ends.
Knight Clinical Trials Information Line
University of Hawaii Cancer Center